1. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. (September 2015) Authors: Camidge, D.R.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Conlan, M.G.; Kerstein, D.; Gettinger, S.N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. (January 2016) Authors: Gettinger, S.N.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 91(2016)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases. (January 2015) Authors: Gettinger, S.N.; Bazhenova, L.; Salgia, R.; Langer, C.J.; Gold, K.A.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Narasimhan, N.I.; Dorer, D.J.; Rivera, V.M.; Clackson, T.; Haluska, F.G.; Camidge, D.R. Journal: Lung cancer Issue: Volume 87(2015)Supplement 1 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 81: Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases. Issue 1 (January 2015) Authors: Gettinger, S.N.; Bazhenova, L.; Salgia, R.; Langer, C.J.; Gold, K.A.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Narasimhan, N.I.; Dorer, D.J.; Rivera, V.M.; Clackson, T.; Haluska, F.G.; Camidge, D.R. Journal: Lung cancer Issue: Volume 87:Issue 1(2015:Jan.) Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. (February 2017) Authors: Hong, D.S.; Dowlati, A.; Burris, H.A.; Lee, J.J.; Brose, M.S.; Farago, A.F.; Bauer, T.M.; Taylor, M.; Shaw, A.T.; Smith, S.; Nanda, N.; Cruikshank, S.; Cox, M.C.; Doebele, R.C. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Genetic landscape of patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. (January 2022) Authors: Tan, D.S-W.; Thomas, M.; Kim, D-W.; Szpakowski, S.; Urban, P.; Mehra, R.; Chow, L.Q.M.; Sharma, S.; Solomon, B.J.; Felip, E.; Camidge, D.R.; Vansteenkiste, J.; Petruzzelli, L.; Pantano, S.; Shaw, A.T. Journal: Lung cancer Issue: Volume 163(2022) Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗